G1 THERAPEUTICS (NASDAQ:GTHX)‘s stock had its “buy” rating reiterated by equities researchers at Cowen and Company in a research note issued on Wednesday.

The analysts wrote, “G1 Therapeutics ended Q2 with $133MM in cash following completion of an IPO in.””

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued a “buy” rating and a $34.00 price objective for the company. Wedbush assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “outperform” rating and a $31.00 price objective for the company. Finally, J P Morgan Chase & Co assumed coverage on G1 THERAPEUTICS in a report on Monday, June 12th. They issued an “overweight” rating and a $23.00 price objective for the company.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) traded down 2.49% during trading on Wednesday, reaching $12.53. The company had a trading volume of 28,749 shares. The company has a 50 day moving average of $15.89 and a 200-day moving average of $16.49. The firm’s market capitalization is $18.54 million. G1 THERAPEUTICS has a 52-week low of $12.04 and a 52-week high of $20.60.

ILLEGAL ACTIVITY NOTICE: “G1 THERAPEUTICS (GTHX) Rating Reiterated by Cowen and Company” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/g1-therapeutics-gthx-rating-reiterated-by-cowen-and-company/1466514.html.

In other G1 THERAPEUTICS news, insider Ra Capital Healthcare Fund Lp purchased 400,000 shares of the stock in a transaction on Monday, May 22nd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $6,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Clay Thorp purchased 133,333 shares of the stock in a transaction on Monday, May 22nd. The stock was acquired at an average price of $15.00 per share, with a total value of $1,999,995.00. The disclosure for this purchase can be found here. Insiders purchased 833,333 shares of company stock valued at $12,499,995 in the last quarter.

Several large investors have recently made changes to their positions in GTHX. Chartwell Investment Partners LLC acquired a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $1,538,000. Victory Capital Management Inc. acquired a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $889,000. Finally, Alps Advisors Inc. acquired a new stake in shares of G1 THERAPEUTICS during the second quarter valued at about $444,000. Institutional investors own 4.57% of the company’s stock.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with Analyst Ratings Network's FREE daily email newsletter.